Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

“Atopic dermatitis, a chronic disease with underlying ... Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

That included Regeneron's prior drug discoveries that spanned from "treatments to prevent blindness, for allergic diseases from asthma to atopic dermatitis, for several forms of cancer ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than ...